Significance of the study: Showing that GLP-1 analog Liraglutide, improves β-cell function in type 2 diabetic individuals, by enhancing clock genes mRNA expression and the AMPK-SRIT1 pathway, may change the approach of Liraglutide treatment, from being an excellent anti-diabetic agent with beneficial effect on the diabetic heart, to a drug with the ability to synchronize body metabolism and improve glucose homeostasis in health and disease. Presently, there are many available drugs for the treatment of type 2 diabetes, but their mode of action does not make any of them more advantageous. If this GLP-1 analog not only reduces glucose, body weight and cardiovascular risk, but also synchronizes the circadian clock, this would make of Liraglutide the drug of choice (immediately after metformin) for the treatment of obesity, early diabetes and for prevention of T2D complications and cardiovascular events in high risk patients, moreover, Liraglutide by influencing clock genes expression, may further prevent several other age related disorders linked to the disruption of clock genes.